Daewon Pharmaceutical Co., Ltd. (KRX:003220)
South Korea · Delayed Price · Currency is KRW 10,300
+70 (0.68%)
At close: Apr 10, 2026
Daewon Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -1,380 | 14,210 | 23,917 | 31,944 | 6,989 |
Depreciation & Amortization | 23,747 | 20,095 | 17,561 | 19,368 | 17,805 |
Loss (Gain) From Sale of Assets | 2,091 | -25.42 | -149.95 | -45.71 | 0.86 |
Asset Writedown & Restructuring Costs | 1,240 | 4,671 | 4,597 | 2,154 | 1,111 |
Loss (Gain) From Sale of Investments | -10,788 | 1,149 | 61.5 | 752.76 | 870.39 |
Loss (Gain) on Equity Investments | -762.1 | -704.2 | -509.42 | -860.08 | -382.62 |
Provision & Write-off of Bad Debts | 197.33 | -204.13 | 230.88 | 887.59 | -250.26 |
Other Operating Activities | 9,396 | 17,840 | 10,638 | 13,240 | 13,054 |
Change in Accounts Receivable | -3,963 | -2,504 | -7,949 | -11,075 | -11,278 |
Change in Inventory | 14,168 | -6,642 | -15,837 | -23,989 | -4,075 |
Change in Accounts Payable | 10,068 | 1,041 | 938.61 | 2,107 | -1,445 |
Change in Income Taxes | 1.32 | 3.21 | -2.03 | 5.05 | -0.32 |
Change in Other Net Operating Assets | -1,909 | -18,894 | 18,239 | -8,075 | 14.07 |
Operating Cash Flow | 42,313 | 30,035 | 51,734 | 26,413 | 22,413 |
Operating Cash Flow Growth | 40.88% | -41.94% | 95.86% | 17.85% | -10.17% |
Capital Expenditures | -29,801 | -34,864 | -12,289 | -8,009 | -4,104 |
Sale of Property, Plant & Equipment | 484.22 | 778.66 | 204.25 | 504.44 | 5.16 |
Cash Acquisitions | - | -7.62 | - | - | -14,602 |
Sale (Purchase) of Intangibles | -12,330 | -18,218 | -8,322 | -5,357 | -7,603 |
Investment in Securities | 6,083 | -12,241 | -893.53 | -9,055 | -16,256 |
Other Investing Activities | 24,526 | 20,882 | -47,331 | 1,520 | 562.08 |
Investing Cash Flow | -11,417 | -42,975 | -68,267 | -20,775 | -41,615 |
Short-Term Debt Issued | 33,669 | 60,421 | 20,081 | 300 | 27,069 |
Long-Term Debt Issued | 29,608 | 42,000 | 22,000 | 3,352 | 45,920 |
Total Debt Issued | 63,277 | 102,421 | 42,081 | 3,652 | 72,989 |
Short-Term Debt Repaid | -22,469 | -45,000 | -234.39 | -468.76 | -10,063 |
Long-Term Debt Repaid | -27,675 | -42,958 | -10,666 | -10,062 | -9,479 |
Total Debt Repaid | -50,144 | -87,958 | -10,900 | -10,530 | -19,541 |
Net Debt Issued (Repaid) | 13,133 | 14,463 | 31,181 | -6,878 | 53,448 |
Issuance of Common Stock | - | - | 106.64 | - | 210.31 |
Repurchase of Common Stock | - | - | - | -6,171 | -85.84 |
Dividends Paid | -6,430 | -6,359 | -7,340 | -4,120 | -3,140 |
Other Financing Activities | -7,632 | -8,402 | -4,434 | -3,241 | -1,906 |
Financing Cash Flow | -929.26 | -297.81 | 19,513 | -20,411 | 48,527 |
Foreign Exchange Rate Adjustments | 172.75 | 312.22 | 32.09 | 45.26 | 40.01 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 1,893 |
Net Cash Flow | 30,140 | -12,926 | 3,013 | -14,727 | 31,258 |
Free Cash Flow | 12,512 | -4,829 | 39,446 | 18,405 | 18,309 |
Free Cash Flow Growth | - | - | 114.32% | 0.52% | 34.58% |
Free Cash Flow Margin | 2.07% | -0.81% | 7.49% | 3.84% | 5.17% |
Free Cash Flow Per Share | 583.77 | -226.83 | 1821.12 | 841.34 | 862.87 |
Cash Interest Paid | 7,526 | 6,513 | 4,421 | 3,230 | 1,858 |
Cash Income Tax Paid | 12,584 | 4,821 | 5,211 | 7,522 | 8,922 |
Levered Free Cash Flow | 11,631 | -28,202 | 2,590 | 10,196 | 14,843 |
Unlevered Free Cash Flow | 16,144 | -22,386 | 5,474 | 12,498 | 16,142 |
Change in Working Capital | 18,365 | -26,996 | -4,611 | -41,027 | -16,784 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.